Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent With Merck

Ratio Therapeutics Inc., a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the monitoring and treatment of cancers, announced the licensing of a Granzyme B-targeted agent for PET imaging applications from Merck, known as MSD outside of the United States and Canada.